GAMMA Investing LLC Increases Position in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

GAMMA Investing LLC lifted its position in Centessa Pharmaceuticals plc (NASDAQ:CNTA) by 29.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,837 shares of the company’s stock after purchasing an additional 865 shares during the quarter. GAMMA Investing LLC’s holdings in Centessa Pharmaceuticals were worth $64,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Centessa Pharmaceuticals by 47.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock valued at $40,000 after buying an additional 826 shares during the period. Quarry LP lifted its stake in Centessa Pharmaceuticals by 47.8% in the 2nd quarter. Quarry LP now owns 9,608 shares of the company’s stock valued at $87,000 after buying an additional 3,108 shares in the last quarter. Sandia Investment Management LP purchased a new position in Centessa Pharmaceuticals in the 2nd quarter valued at about $90,000. Fred Alger Management LLC purchased a new stake in shares of Centessa Pharmaceuticals during the second quarter worth approximately $99,000. Finally, XTX Topco Ltd purchased a new stake in Centessa Pharmaceuticals during the 2nd quarter valued at about $148,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Guggenheim upped their price objective on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a report on Friday, November 15th. TD Cowen started coverage on Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating for the company. BMO Capital Markets upped their price target on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a research note on Monday, September 16th. Morgan Stanley raised Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $11.00 to $26.00 in a research note on Thursday, September 19th. Finally, B. Riley began coverage on shares of Centessa Pharmaceuticals in a report on Thursday, September 19th. They issued a “buy” rating and a $33.00 target price on the stock. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $25.83.

Insider Activity

In other news, insider Gregory M. Weinhoff sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, December 26th. The stock was sold at an average price of $17.04, for a total transaction of $170,400.00. Following the sale, the insider now owns 183,266 shares of the company’s stock, valued at $3,122,852.64. The trade was a 5.17 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Saurabh Saha sold 22,205 shares of the firm’s stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $15.80, for a total value of $350,839.00. Following the completion of the transaction, the chief executive officer now directly owns 663,456 shares of the company’s stock, valued at $10,482,604.80. The trade was a 3.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 368,023 shares of company stock valued at $6,335,574. Insiders own 11.59% of the company’s stock.

Centessa Pharmaceuticals Stock Down 2.9 %

CNTA opened at $15.64 on Monday. Centessa Pharmaceuticals plc has a one year low of $6.65 and a one year high of $18.97. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The stock has a market capitalization of $2.06 billion, a P/E ratio of -10.22 and a beta of 1.53. The business’s 50-day simple moving average is $16.97 and its 200-day simple moving average is $14.45.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.05. Analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.